Catalogue Search | MBRL
هل أنت متأكد أنك تريد إزالة الكتاب من الرف؟
{{itemTitle}}
122,617
نتائج ل
"Respiratory infections"
صنف حسب:
The case of the sneezy popcorn : Annie Biotica solves respiratory system disease crimes
\"Learn about strep throat, Hantavirus, whooping cough, Pneumonia, and the differences between the cold and the flu. Then try to guess the disease in three different cases\"-- Provided by publisher.
Book
Respiratory syncytial virus infection in adults
ABSTRACTHuman respiratory syncytial virus (RSV) belongs to the recently defined Pneumoviridae family, Orthopneumovirus genus. It is a negative sense, single stranded RNA virus that results in epidemics of respiratory infections that typically peak in the winter in temperate climates and during the rainy season in tropical climates. Generally, one of the two genotypes (A and B) predominates in a single season, alternating annually, although regional variation occurs. RSV is a cause of disease and death in children, older people, and immunocompromised patients, and its clinical effect on adults admitted to hospital is clarified with expanded use of multiplex molecular assays. Among adults, RSV produces a wide range of clinical symptoms including upper respiratory tract infections, severe lower respiratory tract infections, and exacerbations of underlying disease. Here we discuss the latest evidence on the burden of RSV related disease in adults, especially in those with immunocompromise or other comorbidities. We review current therapeutic and prevention options, as well as those in development.
Journal Article
Single-Dose Nirsevimab for Prevention of RSV in Preterm Infants
Nirsevimab, a monoclonal antibody with an extended half-life, is designed to protect infants from respiratory syncytial virus disease after a single intramuscular dose. This placebo-controlled trial involving 1447 preterm infants at 164 sites in 23 countries assessed the effectiveness of nirsevimab over 150 days after the dose was administered.
Journal Article
COVID-19 : the pandemic that never should have happened, and how to stop the next one
Over the last 30 years, we learned every lesson needed to stop this coronavirus outbreak in its tracks. We heeded almost none of them. The result is a pandemic on a scale never before seen in our lifetimes. Here, science journalist Debora MacKenzie lays out the full story of how and why it happened: the previous viruses that should have prepared us, the shocking public health failures that paved the way, the failure to contain the outbreak, and most importantly, what we must do to stop this happening again. Offering a compelling history of the most significant recent outbreaks, including SARS, MERS, H1N1, Zika, and Ebola, MacKenzie outlines the lessons we failed to learn from each past crisis. But looking forward, she makes a bold, optimistic argument : this pandemic might finally galvanize the world to take viruses seriously. No one has yet brought together our knowledge of Covid-19 in a comprehensive, informative, and accessible way. But that story can already be told, and Debora MacKenzie's urgent telling is required reading for these times and beyond. Fighting this pandemic and preventing the next one will take political action of all kinds, globally, from governments, the scientific community, and individuals -- and if we act now, it is possible.
Book
SARS
The sudden appearance and rapid spread of Severe Acute Respiratory Syndrome (SARS) in 2003 alerted the world to the fact that emerging infections are a global problem. Living in affluent societies with well-developed healthcare systems does not necessarily protect people from the dangers posed by life-threatening infections. The SARS epidemic tested global preparedness for dealing with a new infectious agent and raised important questions: How did we do, and what did we learn? This book uses the SARS outbreak as a case study to enumerate the generic issues that must be considered when planning the control of emerging infections. Emerging infections are more than just a current biological fashion: the bitter ongoing experience of AIDS and the looming threat of pandemic influenza teach us that the control of infectious disease is a problem that has not been solved. Scientists from a broad range of disciplines — biologists, veterinarians, physicians, and policy makers — all need to prepare. But prepare for what? The book provides an overview of the tasks that must be addressed by a community that wishes to confront emerging infections. While focusing on SARS, the book addresses a whole range of considerations and issues, from the use of new mathematical models to account for the spread of infection across global airline networks, to a discussion of the ethics of quarantining individuals in order to protect communities.
eBook
Efficacy and Safety of a Bivalent RSV Prefusion F Vaccine in Older Adults
In a phase 3 trial, adults (≥60 years of age) received one 120-μg dose of RSVpreF vaccine (17,215) or placebo (17,069). Vaccine efficacy against RSV-associated lower respiratory tract illness was 67 to 86%.
Journal Article
Respiratory Syncytial Virus Prefusion F Protein Vaccine in Older Adults
Respiratory syncytial virus causes clinically significant illness in children and adults. In a placebo-controlled trial, a prefusion stabilized F protein vaccine led to an 83% lower risk of RSV infection.
Journal Article
Toward primary prevention of asthma. Reviewing the evidence for early-life respiratory viral infections as modifiable risk factors to prevent childhood asthma
A first step in primary disease prevention is identifying common, modifiable risk factors that contribute to a significant proportion of disease development. Infant respiratory viral infection and childhood asthma are the most common acute and chronic diseases of childhood, respectively. Common clinical features and links between these diseases have long been recognized, with early-life respiratory syncytial virus (RSV) and rhinovirus (RV) lower respiratory tract infections (LRTIs) being strongly associated with increased asthma risk. However, there has long been debate over the role of these respiratory viruses in asthma inception. In this article, we systematically review the evidence linking early-life RSV and RV LRTIs with asthma inception and whether they could therefore be targets for primary prevention efforts.
Journal Article